ArticleMolecular neurobiology2026
Elevated MicroRNA-146a in Alzheimer's Disease and Its Diagnostic Potential.
Article in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a progressive neurological condition marked by memory impairment and cognitive deterioration. Early diagnosis remains difficult due to the absence of reliable peripheral biomarkers. Circulating microRNAs (miRNAs) have recently gained attention as non-invasive indicators measurable in blood. Among these, microRNA-146a is of particular interest because of its role in inflammatory signaling and its altered expression in AD. This article highlights the diagnostic potential and biological function of microRNA-146a as a peripheral biomarker for Alzheimer's disease. The current study aimed to examine the expression and clinical relevance of microRNA-146a and to assess its possible influence on disease progression in Alzheimer's disease patients. Blood samples were collected after obtaining signed informed consent (No. 3912/2022 MRB) from 50 AD patients and from 50 healthy controls (HC); the miRNA content was screened by RT-PC. The expression of miRNA-146a is significantly greater in the Alzheimer's disease group (4.369 ± 3.168 -fold change) than in the control group (1.056 ± 0.702) (p < 0.001). In order to evaluate miR146a expression efficiency, a receiver operating characteristic (ROC) curve showed miR146a exhibited strong discriminative capability, with an AUC of 0.906 (95% CI 0.83-0.98). At a threshold of 2.21, the sensitivity was 90% and the specificity was 92%, demonstrating exceptional diagnostic efficacy. Logistic regression showed a strong inverse association trend (B = -6.803, OR = 0.001), with borderline statistical significance (p = 0.09). Cross-tabulation with Chi-square test confirmed a highly significant association between miR-146a expression and disease status (p < 0.001). A decision tree using Exhaustive CHAID further supported the finding, achieving 90% classification accuracy with a split point at 2.195. Collectively, these results demonstrate the robustness of miR-146a as a potential biomarker for distinguishing Alzheimer's patients from healthy individuals. An increase was found in the content of expression of microRNA-146a in AD patients compared with HC. Level of microRNA-146a, and correlated with disease; might be used as a biomarker reflecting AD.
Indexed as
Identifiers
42606643What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.